Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post by Toby Eyreon, Lymphoma and CLL specialist Oxford University Hospitals, adding:
“BsAbs in R/R FL
- 139 pts: recent bendamustine ≤24 mo vs naïve
- ORR/CR: 87% / 70% → no difference
- PFS/OS: Similar between groups
- Safety: CRS, ICANS, infections comparable
- Signal: Higher CD8+ T cells → better PFS
Prior bendamustine does not blunt BsAb efficacy.”
Quoting Toby Eyre’s post:
“Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.”
Title: Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma
Authors: Gloria Iacoboni, Emil Kyvsgaard, Víctor Navarro, David Russler-Germain, Katharine Lewis, Alejandro Martin Garcia-Sancho, Itziar Carro, Philip Thompson, Dylan Therwhanger, David Quintela Vilchez, Matthew Ku, Pilar Gómez-Prieto, Evelyn Valencia-Espinoza, Gala Vega, Ana Jiménez-Ubieto, Mariana Beatriz Bastos Oreiro, Ángel Serna, Simon Husby, Beatriz de la Cruz Benito, Jing Luan, Sergi Camarillas, Lucía Medina, Almudena Cabero Martínez, Raúl Córdoba, Miguel Angel Canales, Juan-Manuel Manuel Sancho, Francesc Bosch, Anna Sureda, Stephen Schuster, Chan Cheah, Martin Hutchings, Pere Barba, Pau Abrisqueta
Read the Full Article in Blood Advances.
More posts featuring Mostafa Faisal on OncoDaily.